Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma
Status:
Withdrawn
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This research study is a Phase I/II clinical trial. It is done to determine the best doses
that the investigational drug (P276-00) can be used safely. "Investigational" means that the
drug is still being studied and that research doctors are trying to find out more information
about it such as; the safest dose to use, the side effects it may cause and if it is
effective for treating relapsed/refractory multiple myeloma.
A majority of multiple myeloma patients overexpress a protein that plays a role in regulating
the body's cell cycle called Cyclin D1. The study drug P276-00 is a Cyclin D1 inhibitor under
investigation in the treatment of solid tumors. The researchers therefore believe that Cyclin
D1 should be studied as a therapeutic target in myeloma. In this research study, we are
looking for the highest dose of P276-00 that can be given safely and to see how well it works